AACR 2022 | Effect of chemokine-modulating infusion on local infiltration of immune cells into colorectal tumors

Pawel Kalinski, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses a new method for re-programming cold tumors into hot tumors through systemic treatments. Currently, the re-programming of tumors requires technically challenging targeted drug delivery. Dr Kalinski discusses an alternative approach using a chemokine-modulating infusion. This infusion consists of rintatolimod and interferon-α, which selectively activate chemokines in the tumor microenvironment (TME). This attracts desirable cancer-fighting immune cells to the tumor and improves the tumor’s response to immunotherapy. The chemokine-modulating infusion has low toxicity and can target multiple tumors at different sites. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.